Anebulo Pharmaceuticals is executing on a clear, high-impact strategy—developing an IV cannabis antidote for children—while methodically strengthening its financial position. Success hinges on meeting clinical milestones and efficient use of capital. Investors seeking early-stage biotech plays with public-sector validation and niche-first therapies may find Anebulo a compellingtion.

(Last Price 1.71): Lacking any evidence of a turn higher at the sloped resistance, there is scope lower evidence that Aneb is in a wave 3 correction towards 1.37 region.